Homologous Recombination Pathway Panels Market Report 2026

The homologous recombination pathway panels market size has grown rapidly in recent years. It will grow from $1.12 billion in 2025 to $1.26 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to expansion of precision oncology research, increasing use of genetic testing in cancer diagnosis, growth in hereditary cancer screening programs, wider availability of ngs technologies, rising collaboration between diagnostics and pharma.

The homologous recombination pathway panels market size is expected to see rapid growth in the next few years. It will grow to $2.03 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to increasing adoption of companion diagnostics, rising demand for personalized cancer therapies, expansion of clinical genomics in hospitals, growing use of AI-driven variant interpretation, increasing regulatory approvals for genomic panels. Major trends in the forecast period include increasing adoption of comprehensive hrd testing panels, rising use of ngs-based homologous recombination assays, growing demand for therapy-selection focused panels, expansion of integrated genomic profiling kits, enhanced focus on rapid turnaround diagnostic panels.

The increasing adoption of targeted therapies is expected to drive the growth of the homologous recombination pathway panels market going forward. Targeted therapies are treatments designed to specifically target disease-causing molecules or genetic abnormalities in cells, inhibiting their growth while minimizing damage to normal cells. The rising use of targeted therapies is fueling demand for precision medicine, as patients and healthcare providers prefer treatments that are more effective and have fewer side effects compared to conventional therapies. Homologous recombination (HR) pathway panels support targeted therapies by identifying patients likely to respond to DNA damage-targeting drugs, enabling clinicians to tailor treatment plans and enhance therapeutic outcomes. For instance, in July 2023, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, the number of gene therapies in Phase III clinical trials increased by 10% in the fourth quarter of 2023, marking the first quarterly rise since the third quarter of 2022. Hence, the growing adoption of targeted therapies is propelling the expansion of the homologous recombination pathway panels market.

The rising number of clinical trials is expected to propel the growth of the homologous recombination pathway panels market going forward. Clinical trials are controlled research studies conducted in humans to evaluate the safety and efficacy of medical interventions. The increase in clinical trials is driven by the growing prevalence of chronic and complex diseases, which creates a demand for novel and effective treatments. Clinical trials support homologous recombination pathway (HRP) panels by validating their ability to detect patients with HR gene defects, guiding targeted therapies, and evaluating treatment outcomes in real-world patient populations. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, the number of industry clinical trials initiated in the UK increased to 426 in 2023, from 411 in 2022. Thus, the expanding number of clinical trials is fueling the growth of the homologous recombination pathway panels market.

Companies operating in the homologous recombination pathway panels market are focusing on developing advanced comprehensive genomic profiling solutions to identify DNA repair deficiencies, guide targeted therapies, and enable personalized treatment strategies for cancer patients. Comprehensive genomic profiling refers to an advanced testing approach that examines hundreds of genes simultaneously to identify genetic alterations, biomarkers, and molecular signatures, enabling precision medicine and informed therapeutic strategies. For example, in September 2024, Integrated DNA Technologies, a US-based biotechnology company, launched Archer homologous recombination deficiency (HRD) technology to detect homologous recombination deficiencies and guide targeted cancer therapies. These technologies assess homologous recombination deficiency (HRD) in solid tumors to enhance comprehensive genomic profiling (CGP) for cancer research. Its purpose is to detect key biomarkers such as HRD alongside MSI and TMB from low-input samples, supporting precision medicine via flexible NGS panels without workflow overhauls. Advantages include AMP chemistry for standalone, spike-in, or integrated use, optimizing resources and customization.

Major companies operating in the homologous recombination pathway panels market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Integrated DNA Technologies Inc., NeoGenomics Laboratories Inc., Promega Corporation, Invitae Corporation, Caris Life Sciences Inc., Fulgent Genetics Inc., Foundation Medicine Inc., Metropolis Healthcare Limited, AmoyDx Diagnostics Co. Ltd., CD Genomics, iGeneTech Inc., and Paragon Genomics Inc.

Tariffs are impacting the homologous recombination pathway panels market by increasing costs of imported sequencing instruments, reagents, bioinformatics software licenses, and specialized laboratory consumables used in NGS-based diagnostics. Diagnostic laboratories and research institutes in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces pricing pressure on sequencing reagents. These tariffs are increasing testing costs and influencing procurement cycles. However, they are also encouraging local reagent manufacturing, regional sequencing infrastructure development, and investments in domestically produced genomic testing solutions.

The homologous recombination pathway panels market research report is one of a series of new reports that provides homologous recombination pathway panels market statistics, including homologous recombination pathway panels industry global market size, regional shares, competitors with a homologous recombination pathway panels market share, detailed homologous recombination pathway panels market segments, market trends and opportunities, and any further data you may need to thrive in the homologous recombination pathway panels industry. This homologous recombination pathway panels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Homologous recombination pathway panels refer to specialized genetic testing panels that analyze a set of genes involved in the homologous recombination (HR) DNA repair pathway, which is responsible for accurately repairing double-strand breaks in DNA to maintain genomic stability. These panels are widely used in cancer diagnostics, hereditary cancer risk assessment, and precision oncology to detect mutations that can influence cancer susceptibility, prognosis, and response to targeted therapies such as poly ADP ribose polymerase inhibitors.

The key panel types of homologous recombination pathway panels include comprehensive homologous recombination deficiency panels, focused or core homologous recombination repair gene panels, custom or research panels, and integrated genomic profiling kits. Comprehensive homologous recombination deficiency panels are designed to detect deficiencies in homologous recombination repair pathways for clinical and research applications. These panels employ technologies such as next-generation sequencing, polymerase chain reaction, microarray-based panels, and other molecular diagnostics. Applications include cancer research, studies of genetic disorders, drug discovery, clinical diagnostics, and more, with end users including hospitals and clinics, diagnostic laboratories, research institutions, biotechnology companies, and pharmaceutical firms.

The homologous recombination pathway panels market consists of sales of the homologous recombination deficiency complete panels, the handle homologous recombination repair next-generation sequencing panels, homologous recombination deficiency focus panels, breast cancer susceptibility gene research assays, homologous recombination repair pathway predesigned panels, and the comprehensive assays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.